About the Company
aTyr Pharma is a public biotherapeutics company (Nasdaq: LIFE) that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease (ILD), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LIFE News
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in ...
LIFE aTyr Pharma, Inc.
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is ...
Buy Rating Affirmed for aTyr Pharma as Lead Candidate efzofitimod Advances in Clinical Trials with Solid Financial Footing
Begin your TipRanks Premium journey today. aTyr Pharma (LIFE) Company Description: aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline ...
Atyr Pharma: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (LIFE) on Thursday reported a loss of $14.8 million in its fourth quarter. The San Diego-based company said it had a loss of 25 cents per share.
aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first ...
Q4 2023 aTyr Pharma Inc Earnings Call
Ashlee Dunston; Director of IR & Corporate Communications; aTyr Pharma, Inc Sanjay Shukla; President, CEO & Director; aTyr Pharma, Inc Jill Broadfoot; CFO; aTyr ...
aTyr Pharma, Inc. (LIFE)
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its ...
aTyr Pharma Inc LIFE
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...